BIOTECH COMPANY AMGEN 3Q PROFIT DROPS 63 PERCENT ON SETTLEMENT OTHER CHARGES AND HIGHER COSTS

October 25, 2011

TRENTON, N.J. — Amgen Inc. said Monday that its third-quarter profit plunged by more than 60 percent, mainly because of a $780 million charge for a planned settlement of multiple federal and state investigations of marketing and other practices. The world’s largest biotech drugmaker also had higher costs for administration and production, but it still beat Wall Street estimates excluding one ...



Full Story Below

Rapid Response
Free Case Evaluation


The Help You Need,
When You Need it Most

Please Type The Number You See Below

8562

More from Settlement News Directory

Claim Your Attorney Profile
Lawyer Central Legal Sites
  Injury     Bankruptcy     Dangerous Products     Family     Real Estate     Estate Planning     Immigration     Disability     Employment     Toxic Torts     Criminal     Litigation  

Find us on Facebook! Follow us on Twitter!

Lawyer State Directories
Alabama | Alaska | Arizona | Arkansas | California | Colorado | Connecticut | Delaware | Florida | Georgia | Hawaii | Idaho | Illinois | Indiana | Iowa | Kansas | Kentucky | Louisiana | Maine | Maryland | Massachusetts | Michigan | Minnesota | Mississippi | Missouri | Montana | Nebraska | Nevada | New Hampshire | New Jersey | New Mexico | New York | North Carolina | North Dakota | Ohio | Oklahoma | Oregon | Pennsylvania | Rhode Island | South Carolina | South Dakota | Tennessee | Texas | Utah | Vermont | Virginia | Washington | West Virginia | Wisconsin | Wyoming |
May 24, 2012
Terms & Conditions
Site Map


Follow @lawyercentral